AbbVie sees 37% drop in Humira sales this year as biosimilars hit U.S. market
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to AbbVie sees 37% drop in Humira sales this year as biosimilars hit U.S. market
February 9, 2023 1:39 PM EST
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $180.00 price target on Abbvie (NYSE: ABBV) as Humira guidance removes overhang.
The analyst commented, "Following ABBV's 4Q2022 earnings call, we are reiterating our Buy rating as 1) we believe that the guidance provided... More
February 9, 2023 10:00 AM EST
AbbVie (NYSE: ABBV) shares are up more than 3% in early Thursday trading after the company topped earnings estimates for the fourth quarter.
Earnings came in at $3.60 per share, $0.07 better than the analyst estimate of $3.53. However, the biotech firm missed the analyst consensus revenue forecast of $15.33 billion, coming in at $15.12 billion.
The company's results included an unfavorable impact of $0.13 per share related to the fourth-quarter 2022 acquired IPR&D and milestones expense.
The... More
